Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Current status of EGFR/ErbB inhibitors in non-small cell lung carcinoma].

Medicina clinica - 1 Apr 2016

Álvarez-Fernández Carlos, Esteban-González Emilio

Abstract excerpt

In the last 10 years, there has been a major change in the treatment of lung cancer (LC). The discovery of activating mutations in the epidermal growth factor receptor (EGFR) in some histological subtypes of LC and its sensitivity to tyrosine kinase inhibitors (TKI) has represented a substantial advance in the treatment of this entity. Until then, the only available option to treat this type of tumour was based...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Afatinib
Share to Erlotinib Hydrochloride
Share to Gefitinib

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genes, erbB-2

Share to Precision Medicine

Share to Protein Kinase Inhibitors

Share to Quinazolines

Share to Receptor, ErbB-2

Source

Identifiers

PMID: 27426241
DOI: 10.1016/S0025-7753(16)30256-1

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Current status of EGFR/ErbB inhibitors in non-small cell lung carcinoma].PMID 27426241Read ↗

[Inhibitors of the EGFR pathway in non small cell lung cancer: what's new in 2007?].Semantic proximity Read ↗

Epidermal growth factor receptor inhibition in lung cancer: status 2012.Semantic proximity Read ↗

[Biomarkers and targeted therapies in non-small cell lung cancer: present and future treatments].Semantic proximity Read ↗

Targeted therapies and immunotherapy in non-small-cell lung cancerSemantic proximity Read ↗

[Molecular profiling of non-small cell lung cancer].Semantic proximity Read ↗

New Scope of Targeted Therapies in Lung Carcinoma.Semantic proximity Read ↗

[From rare mutations to classical ones, inhibition of signaling pathways in non-small cell lung cancer].Semantic proximity Read ↗

Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies.Semantic proximity Read ↗

[News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)].Semantic proximity Read ↗

[Molecular pathology of pulmonary carcinomas].Semantic proximity Read ↗

[New targets and new drugs in thoracic oncology].Semantic proximity Read ↗

Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.